AIM: To explore the correlation between Twist-related protein (Twist)1, fibroblast growth factor receptor (FGFR)2 and gastric adenocarcinoma differentiation and progression. METHODS: We evaluated Twist1 and FGFR2 in 52 gastric adenocarcinoma samples by immunohistochemistry and quantitative real time polymerase chain reaction, and analyzed the correlation between Twist1, FGFR2 and cancer differentiation. We also detected Twist1 and FGFR2 expression in gastric adenocarcinoma cell lines, and evaluated Twist1 influence on FGFR2 expression. In addition, we studied the role of FGFR2 in Twist1-promoted cancer progression, including proliferation, invasion and epithelial-mesenchymal transition (EMT). RESULTS: Twist1 and FGFR2 were detected in almost all the gastric adenocarcinoma samples. Twist1 (P = 0.0213) and FGFR2 (P = 0.0310) mRNA levels had a significant association with gastric adenocarcinoma differentiation. Moreover, Twist1 and FGFR2 expression in poorly differentiated cells (SNU-1 and SNU-16) was notably higher than in well-differentiated cells (MKN-7 and MKN-28). In poorly differentiated gastric adenocarcinomas, FGFR2 mRNA level was significantly positively correlated with Twist1 mRNA level (P = 0.004). Twist1 was proved to promote FGFR2 by regulating Twist1 expression by knockdown and overexpression. Additionally, Twist1 could induce proliferation, invasion and EMT in gastric cancer; of these, FGFR2 was required for invasion and EMT, rather than proliferation. CONCLUSION: Twist1 and FGFR2 are highly associated with differentiation of gastric adenocarcinoma; Twist1 can facilitate invasion and EMT in gastric adenocarcinoma via promotion of FGFR2 expression.
AIM: To explore the correlation between Twist-related protein (Twist)1, fibroblast growth factor receptor (FGFR)2 and gastric adenocarcinoma differentiation and progression. METHODS: We evaluated Twist1 and FGFR2 in 52 gastric adenocarcinoma samples by immunohistochemistry and quantitative real time polymerase chain reaction, and analyzed the correlation between Twist1, FGFR2 and cancer differentiation. We also detected Twist1 and FGFR2 expression in gastric adenocarcinoma cell lines, and evaluated Twist1 influence on FGFR2 expression. In addition, we studied the role of FGFR2 in Twist1-promoted cancer progression, including proliferation, invasion and epithelial-mesenchymal transition (EMT). RESULTS:Twist1 and FGFR2 were detected in almost all the gastric adenocarcinoma samples. Twist1 (P = 0.0213) and FGFR2 (P = 0.0310) mRNA levels had a significant association with gastric adenocarcinoma differentiation. Moreover, Twist1 and FGFR2 expression in poorly differentiated cells (SNU-1 and SNU-16) was notably higher than in well-differentiated cells (MKN-7 and MKN-28). In poorly differentiated gastric adenocarcinomas, FGFR2 mRNA level was significantly positively correlated with Twist1 mRNA level (P = 0.004). Twist1 was proved to promote FGFR2 by regulating Twist1 expression by knockdown and overexpression. Additionally, Twist1 could induce proliferation, invasion and EMT in gastric cancer; of these, FGFR2 was required for invasion and EMT, rather than proliferation. CONCLUSION:Twist1 and FGFR2 are highly associated with differentiation of gastric adenocarcinoma; Twist1 can facilitate invasion and EMT in gastric adenocarcinoma via promotion of FGFR2 expression.
Entities:
Keywords:
Cancer differentiation; Cancer progression; Fibroblast growth factor receptor 2; Gastric adenocarcinoma; Twist-related protein 1
Authors: Helen Davies; Chris Hunter; Raffaella Smith; Philip Stephens; Chris Greenman; Graham Bignell; Jon Teague; Adam Butler; Sarah Edkins; Claire Stevens; Adrian Parker; Sarah O'Meara; Tim Avis; Syd Barthorpe; Lisa Brackenbury; Gemma Buck; Jody Clements; Jennifer Cole; Ed Dicks; Ken Edwards; Simon Forbes; Matthew Gorton; Kristian Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jonathon Hinton; David Jones; Vivienne Kosmidou; Ross Laman; Richard Lugg; Andrew Menzies; Janet Perry; Robert Petty; Keiran Raine; Rebecca Shepherd; Alexandra Small; Helen Solomon; Yvonne Stephens; Calli Tofts; Jennifer Varian; Anthony Webb; Sofie West; Sara Widaa; Andrew Yates; Francis Brasseur; Colin S Cooper; Adrienne M Flanagan; Anthony Green; Maggie Knowles; Suet Y Leung; Leendert H J Looijenga; Bruce Malkowicz; Marco A Pierotti; Bin T Teh; Siu T Yuen; Sunil R Lakhani; Douglas F Easton; Barbara L Weber; Peter Goldstraw; Andrew G Nicholson; Richard Wooster; Michael R Stratton; P Andrew Futreal Journal: Cancer Res Date: 2005-09-01 Impact factor: 12.701
Authors: T Miki; D P Bottaro; T P Fleming; C L Smith; W H Burgess; A M Chan; S A Aaronson Journal: Proc Natl Acad Sci U S A Date: 1992-01-01 Impact factor: 11.205
Authors: P M Pollock; M G Gartside; L C Dejeza; M A Powell; M A Mallon; H Davies; M Mohammadi; P A Futreal; M R Stratton; J M Trent; P J Goodfellow Journal: Oncogene Date: 2007-05-21 Impact factor: 9.867
Authors: Tony Navas; Robert J Kinders; Scott M Lawrence; Katherine V Ferry-Galow; Suzanne Borgel; Melinda G Hollingshead; Apurva K Srivastava; Sergio Y Alcoser; Hala R Makhlouf; Rodrigo Chuaqui; Deborah F Wilsker; Mariam M Konaté; Sarah B Miller; Andrea Regier Voth; Li Chen; Tomas Vilimas; Jyothi Subramanian; Lawrence Rubinstein; Shivaani Kummar; Alice P Chen; Donald P Bottaro; James H Doroshow; Ralph E Parchment Journal: Cancer Res Date: 2019-11-15 Impact factor: 12.701
Authors: Jinglin Zhang; Patrick M K Tang; Yuhang Zhou; Alfred S L Cheng; Jun Yu; Wei Kang; Ka Fai To Journal: Cells Date: 2019-06-25 Impact factor: 6.600
Authors: Ana Vila; Miguel Abal; Laura Muinelo-Romay; Carlos Rodriguez-Abreu; José Rivas; Rafael López-López; Clotilde Costa Journal: PLoS One Date: 2016-10-06 Impact factor: 3.240